Background Image
Table of Contents Table of Contents
Previous Page  1385 / 1498 Next Page
Information
Show Menu
Previous Page 1385 / 1498 Next Page
Page Background

Effector

cell

ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity

FcγRIIIa

Complement

Increased direct cell death

Type II antibody & elbow-hinge modification

Increased ADCC

Higher affinity to the 'ADCC receptor' FcγRIIIa

(GlycoMab TM technology) &

Reduced CD20 internalization (?)

Reduced CDC activity

Type II antibody

Enhanced activity in combination with

chemotherapy

Type II CD20 antibody

Putative mechanism(s) of action